Published in Eur Urol on June 17, 2008
Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. PLoS One (2014) 0.81
α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume. World J Urol (2010) 0.80
Management of urinary incontinence. P T (2012) 0.76
Therapeutic options in the treatment of benign prostatic hyperplasia. Patient Prefer Adherence (2009) 0.75
Non-Hormonal treatment of BPH/BOO. Indian J Urol (2014) 0.75
Pediatrics: combining antimuscarinics shows promise for overactive bladder. Nat Rev Urol (2010) 0.75
Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 0.75
Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 0.75
Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial. Chin Med J (Engl) (2016) 0.75
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J Urol (2010) 3.05
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer (2008) 2.85
Dipstick pseudohematuria: unnecessary consultation and evaluation. J Urol (2009) 2.75
Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology (2011) 2.68
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol (2008) 2.58
Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int (2011) 2.41
Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol (2011) 2.38
Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology (2012) 2.36
HIV prevention: male circumcision comparison between a nonsurgical device to a surgical technique in resource-limited settings: a prospective, randomized, nonmasked trial. J Acquir Immune Defic Syndr (2012) 2.34
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol (2012) 2.26
One-arm, open-label, prospective, cohort field study to assess the safety and efficacy of the PrePex device for scale-up of nonsurgical circumcision when performed by nurses in resource-limited settings for HIV prevention. J Acquir Immune Defic Syndr (2013) 2.18
Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol (2009) 2.18
Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol (2009) 2.13
Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology (2011) 2.12
Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int (2011) 2.12
Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol (2004) 2.12
Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology (2011) 2.07
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Current role for combination therapy in male LUTS. Arch Esp Urol (2010) 2.03
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Noninvasive methods to evaluate bladder obstruction in men. Int Braz J Urol (2013) 1.98
Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc (2011) 1.89
Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int (2011) 1.88
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol (2012) 1.85
The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn (2012) 1.82
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol (2009) 1.81
Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology (2011) 1.78
Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology (2006) 1.75
Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol (2005) 1.72
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol (2010) 1.63
Office based flexible cystoscopy may be less painful for men allowed to view the procedure. J Urol (2007) 1.62
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
Prospective evaluation of prostate cancer risk in candidates for inguinal hernia repair. J Am Coll Surg (2009) 1.59
Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. Urology (2010) 1.58
Age related pathogenesis of nocturia in patients with overactive bladder. J Urol (2007) 1.57
Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate (2014) 1.56
Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol (2008) 1.53
Transurethral microwave thermotherapy for benign prostate hyperplasia: separating truth from marketing hype. J Urol (2004) 1.50
High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology (2004) 1.50
Determining the course of the dorsal nerve of the clitoris. Urology (2008) 1.50
Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol (2008) 1.49
Association of urological symptoms and chronic illness in men and women: contributions of symptom severity and duration--results from the BACH Survey. J Urol (2008) 1.49
Concordance of near infrared spectroscopy with pressure flow studies in men with lower urinary tract symptoms. J Urol (2010) 1.48
Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int (2009) 1.46
Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int (2010) 1.46
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience. Int J Urol (2011) 1.46
Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy? Urology (2013) 1.45
Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol (2008) 1.45
Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int (2013) 1.44
Early infectious complications with transponder placement for external beam radiation therapy for prostate cancer. BJU Int (2012) 1.41
Fesoterodine dose response in subjects with overactive bladder syndrome. Urology (2008) 1.41
Using a saturation biopsy scheme increases cancer detection during repeat biopsy in men with high-grade prostatic intra-epithelial neoplasia. Urology (2011) 1.40
Percentage of free prostate-specific antigen: implications in modern extended scheme prostate biopsy. Urology (2010) 1.40
Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology (2011) 1.40
Incomplete prenatal torsion of the testicle--a successful salvage. Urology (2011) 1.39
Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples. Urology (2011) 1.38
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. J Urol (2013) 1.37
Re: LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. J Urol (2012) 1.37
Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol (2007) 1.36
Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology (2006) 1.35
Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol (2008) 1.35
Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol (2009) 1.34
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials (2003) 1.33
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int (2011) 1.31
Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int (2008) 1.31
Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology (2008) 1.30
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol (2007) 1.27
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol (2011) 1.26
Interstitial cystitis and panic disorder: a potential genetic syndrome. Arch Gen Psychiatry (2004) 1.20
Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology (2004) 1.20
Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int (2011) 1.19
Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial. J Urol (2009) 1.18
Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol (2009) 1.18
Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int (2009) 1.17
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol (2008) 1.16
Temporal trends in adoption of and indications for the artificial urinary sphincter. J Urol (2009) 1.15
Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol (2008) 1.13
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. J Urol (2008) 1.13
Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology (2006) 1.12
Importance of additional "extreme" anterior apical needle biopsies in the initial detection of prostate cancer. Urology (2010) 1.11
Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int (2012) 1.11
Defining the role of NMP22 in bladder cancer surveillance. World J Urol (2007) 1.10
The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol (2008) 1.10
A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int (2009) 1.09
Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey. BJU Int (2008) 1.09